Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Dabrafenib, Pembrolizumab in melanoma and non-small-cell lung cancer, run by Immuneering Corporation, active and no longer recruiting.
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05585320 by Immuneering Corporation, with 209 participants enrolled, started 2022-10-31 and due to reach its primary completion in 2026-06. Interventions recorded: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E). Conditions listed: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Dabrafenib, Melanoma, Pembrolizumab.
Shares Dabrafenib, Paclitaxel / nab-paclitaxel, Pembrolizumab.
Shares Dabrafenib, Melanoma, Pembrolizumab.
Shares Dabrafenib, Melanoma.
Shares Dabrafenib, Melanoma.
Shares Dabrafenib, Melanoma, Non-small-cell lung cancer.
Shares Dabrafenib, Pembrolizumab, Non-small-cell lung cancer.